Article Text

Download PDFPDF
Treatment results in women with clinical stage I and pathologic stage II endometrial carcinoma
  1. J. J. Jobsen1,
  2. E. M. J. Schutter2,
  3. J. H. Meerwaldt1,
  4. J. Van Der Palen3,
  5. R. Van Der Sijde4 and
  6. L. Naudin Ten Cate5
  1. 1Department of Radiation Oncology, Departments of
  2. 2Obstetrics and Gynaecology and
  3. 3Epidemiology, Medisch Spectrum Twente, Enschede;
  4. 4Department of Obstetrics and Gynaecology, Streekziekenhuis Midden Twente, Hengelo
  5. 5Laboratorium Pathologie Oost Nederland, Enschede, The Netherlands.
  1. Address correspondence and reprint requests to: Jan J. Jobsen, MD, Department of Radiation Oncology, Medisch Spectrum Twente, Haaksbergerstraat 55, 7513 ER Enschede, The Netherlands. Email: rath_mst{at}euronet nl.


The aim of this study is to report survival and results of therapy and possible prognostic factors in women with pathologic stage II endometrial carcinoma. Forty-two patients with pathologic stage II endometrial carcinoma were treated at the department of Radiation Oncology of the Medisch Spectrum Twente between 1987 and 1998. All patients received external radiotherapy following standard surgical procedures and no adjuvant systemic therapy was given. From the 42 patients 21 had a pathologic stage IIA and 21 stage IIB. The median follow-up was 62 months. The overall recurrence rate was 21.5% (9/42). Seven patients had distant metastasis, of which three also had locoregional recurrence, vaginal vault and/or pelvic. The presence of myometrial invasion (> ½) and/or lymph-angioinvasion showed a significant relation with distant metastasis (P = 0.017). Stage IIB showed more recurrences, 33% (7/21). There was a significant different 5-year disease specific survival for stage IIA and IIB, respectively, 95% and 74% (P = 0.0311). Patients with a differentiation grade 3 and stage IIB showed a significantly poorer (P = 0.003) 5-year survival of 48.6% (P = 0.003). Results obtained in the present series of patients are in accordance with the literature. The present treatment policy seems justified, except for patients with pathologic stage IIB and grade 3, in which a more aggressive treatment should be considered.

  • endometrial carcinoma
  • pathologic stage II
  • prognostic factors

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.